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Cancer is known as a leading cause of death worldwide. In the last two decades, the incidence of cancer
has been dramatically increased mostly due to lifestyle changes. The importance of this issue has
attracted further attention to discover novel therapies to prevent and treat cancers. According to pre-
vious studies, drugs used to treat cancer have shown signiﬁcant limitations. Therefore, the role of herbal
medicines alone or in combination with chemotherapy drugs has been extensively studied in cancer
treatment. Cinnamon is a natural component showing a wide range of pharmacological functions
including anti-oxidant, anti-microbial and anti-cancer activities. Impaired apoptosis plays critical roles in
the initiation and progression of cancer. Increasing evidence indicates that cinnamon, as a therapeutic
agent, has anti-cancer effects via affecting numerous apoptosis-related pathways in cancer cells. Here, we
highlighted anticancer properties of cinnamon, particularly through targeting apoptosis-related
mechanisms.
© 2019 Elsevier Masson SAS. All rights reserved.Contents
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served.1. Introduction
Cancer is one of the most threatening health problems in the
world. In human body, new cells are continually generated in order
to repair damaged tissues. Ordinarily, cell proliferation and death
occur in a balanced manner. In cancerous conditions, cellular
growth, division and death are deregulated. The result of such a
deregulation is probably an unusual blood or lymph ﬂuid in body,
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Apoptosis is a highly investigated process in pathological or
normal conditions [1]. Due to the signiﬁcant role of this process in
different pathological conditions, it is important to understand its
related mechanisms to discover novel therapies. In cancer, there is
an imbalance between cell division and death. In fact, decisive cell
death does not occur due to the lack of death signals [1,2].
Cinnamon, a traditional herbal medicine, has different biological
properties such as anti-tumor, anti-diabetic, anti-inﬂammatory,
anti-microbial and anti-oxidant activities. Also, it is able to affect
apoptosis. This review describes the potential of cinnamon in the
modulation of neoplastic processes through affecting different
biochemical signaling pathways, especially apoptosis.
2. Cinnamon and cancer
It has been predicted by the International Agency for Research
on Cancer (IARC) (2012) that despite all strategies used for cancer
treatment, the world is experiencing an increasing burden of can-
cer. Notably, it has been reported that 8.2 million cancer-related
deaths as well as 14.1 million newly diagnosed patients have
been registered in 2012 worldwide. According to the estimations of
Globocan 2012, the number of new cancer cases will reach 19.3
million by 2025 [3]. of the increasing trend in cancer occurrence
calls for further research to ﬁnd more efﬁcacious drugs [4].
Chemotherapy, targeted therapies, radiotherapy, surgery, immu-
notherapy and other methods, such as transplantation of stem cells,
are the main modalities for cancer treatment [4]. All these modal-
ities have major barriers and limitations. The most frequently used
cancer treatments (i.e. radiotherapy and chemotherapy) have two
main hurdles including have recurrence and many side effects [4].
Fig.1 shows amajor difference between healthy and cancerous cells
based on their attachment to basement membranes. One of the
main research directions in the recent decades pertains to the
discovery of novel strategies to ﬁght against cancer via natural di-
etary elements including medicinal plants and phytochemicals [5].
Cinnamon is a spice that has been widely utilized from the
ancient era [6]. This spice has been extensively studies with respect
to its potential in improving human health. Cinnamon has anti-
cancer activities that are exerted through multiple molecular
mechanisms [7]. Fig. 2 indicates chemical structure of a number of
main active components of cinnamon.
One of the most important properties of any potential anti-
carcinogenic compound is its ability to interfere with cancer cell
viability. Numerous studies have indicated the anti-proliferative
effects of cinnamon against various cancer cells. Signiﬁcant anti-
proliferative function of cinnamon extract (CE) was shown in
three hematological cancer cell lines i.e. U937, Wurzburg and Jurkat
cells [8]. Each cell type exhibited a dose-dependent decrease in
viability when treated with a dose range between 0.05 and 0.2mg/Fig. 1. Schematic presentation of themL of CE. Among the tested cells, it was observed that Wurzburg
cells possessed the greatest sensitivity to CE. This ﬁnding suggests
differential and cell-speciﬁc properties of cinnamon in regulating
cell proliferation [8]. Moreover, anti-proliferative activity of CE was
revealed in SiHa, a cervical cancer cell line, when treated with
various concentrations of CE (10, 20, 40 and 80 mg/ml) [9]. In SiHa
cells treated with CE at a concentration of 80 mg/ml, a dose-
dependent decline in growth kinetics was observed compared
with untreated cells. In addition, clonogenic assays conﬁrmed the
anti-proliferative potential of CE [9].
Due to the interrelationship between immunity and inﬂam-
matory processes contributing to cancer progression, immuno-
therapy is known as a potential therapy against cancer. Currently,
there is an increasing interest to use natural products for
strengthening the immune system. CD8þT cells, known also as
killer T cells or cytotoxic T lymphocytes, function as major players
in restricting the carcinogenic processes. Intra-tumoral injection or
oral administration of CE signiﬁcantly decreased tumor cell prolif-
eration via acceleration of the cytolytic activities of CD8þT cells
in vivo. Compared with the control group, cinnamon extract
induced the expression of cytolytic mediators such as Tumor ne-
crosis factor-a (TNF-a) and interferon gamma (IFNc). It was shown
that cinnamon signiﬁcantly up-regulated perforin and granzymes B
and C levels, thereby inducing apoptosis [7]. Due to its pivotal role
in tumor cell metastasis, angiogenesis plays an important role in
cancer progression. Hypoxia inducible factor 1 alpha (HIF-1a) and
cyclooxygenase 2 (COX-2) contribute to the angiogenesis process. A
signiﬁcant down-regulation of HIF-1a and COX-2 expression was
observed following treatment of Clone M3 and B16F10 melanoma
cells with at different concentrations (0.1, 0.2, 0.3, 0.4 and 0.5mg/
ml) of CE for 24 h. CE completely blocked COX-2 expression at a
dose of 0.5mg/ml [10]. CE showed the same effects in mice treated
by intra-tumoral injections (IT) or oral administration (OA) for 30
days. OA had greater capability in down-regulating both translation
and transcription of HIF-1a and COX-2 compared with IT. COX-2
transcription was decreased by 40% in the IT group, while a 9%
decrease was observed in the OA group [10].
When treating cancer, regulating the expression of growth fac-
tors is one of the most essential aims. CE signiﬁcantly inhibited the
transcription and translation of various growth factors (e.g. VEGF-a,
FGF, EFG and TGF-b) in a dose-dependent (0.5 and 0.3mg/ml)
manner in melanoma cell lines Clone M3 and B16F10, while these
effects were not seen when using similar concentrations of CE in
healthy cells [10]. Also, the essential oil of cinnamon (EOC) has been
shown to suppress EGFR-TK (epidermal growth factor receptor-
tyrosine kinase) activities in laryngeal squamous cell carcinoma
cell line Hep-2, which led to 43.5% decrease in tumor burden [11].
Essential oil of cinnamon bark (CBEO) also showed similar effects in
pre-inﬂamed human dermal ﬁbroblasts and signiﬁcantly down-
regulated plasminogen activator inhibitor-1 (PAI-1), epidermalbasic properties of cancer cells.
Fig. 2. Chemical structures of different active compounds of cinnamon.
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In addition to the anti-proliferative activities of cinnamon, in-
dividual changes in cancer cell morphology were shown following
the use of cinnamon either as extract or as individual active con-
stituent(s). Oral or intra-tumoral injection of CE to a mouse mela-
noma model signiﬁcantly reduced tumor growth after 22 days of
therapy as determined by tumor weight measurement. CE sup-
pressed metastasis occurrence by decreasing weight and dimen-
sion of spleen drainage and lymph nodes compared to the control
[10].
CBEO derived from Cinnamomum zeylanicum up-regulates the
expression of some inﬂammatory cytokines including monocyte
chemo-attractant protein-1, monokine induced by gamma inter-
feron, interferon gamma-induced protein 10 and interferon-
inducible T cell alpha chemo-attractant in the human dermal
ﬁbroblast system. Also, CBEO signiﬁcantly reduced the level of
macrophage colony-stimulating factor (M-CSF) as an immuno-
modulatory protein [12].
In addition to CE, various active compounds of cinnamon (i.e.
eugenol, BCA, HCA and cinnamaldehyde) increased the cytotoxicity
of different types of cancer cells. Eugenol is a compound which
could be found in different plants including cinnamon, basil, lemon
balm and nutmeg. Eugenol is a key compounds in cinnamon, which
shows a wide ranges of pharmacological activities [13]. Following
treatment with eugenol at a concentration ranged from 10 mM to
1Mm for 24 h, the proliferation rate of HeLa cells was decreased.
Although no cytotoxicity on normal lymphocytes was observed at500 mM, a similar concentration caused a 50% suppression in the
growth of HeLa cells [14]. Cytotoxic impact of eugenol was seen
against colon cancer cells HT-29 and HCT-15, of which the former
cell line had a higher sensitivity to eugenol [15]. Eugenol showed
considerable anti-proliferative effects in HL-60 cell, a promyelo-
cytic leukemia cell line, with an IC50 of 23.7mM [16]. Using
eugenol in combination with gemcitabine (a chemotherapy drug)
showed a strong chemo-sensitizing impact. A combination of
eugenol (150 mM; sublethal dose) and gemcitabine (15mM)
increased the cytotoxicity of both compounds in HeLa cells (47%
viable cells) compared with anti-proliferative properties of using
each compound alone (84% and 73% of viable cells for eugenol and
gemcitabine, respectively) [14]. The chemo-sensitizing effect of
eugenol was also reported in prostate cancer cells, in which the
combination of 2-methoxyestradiol (2ME2) and eugenol synergis-
tically increased the cytotoxic effects against androgen-
independent PC-3 cell line. IC50 of 2-ME2 and eugenol, when
used separately, were 82 mg/ml and 1 mM, respectively. Neverthe-
less, the combination (41 mg/ml eugenol þ 0.5 mM 2ME2) showed a
50% growth suppression. In addition, the combination inhibited
anchorage-independent growth of PC-3 cells; however, a consid-
erable effect was not observed when either eugenol or 2-ME2
alone. Therefore, the combination efﬁciently declined anchorage-
independent/dependent growth of prostate cancer cells [17].
In a DMBA croton oil-induced skin tumor animal model, neo-
plastic morphological alterations were inhibited at the pre-
malignant phase following pre-treatment of animals with
eugenol. It was found that the dimension of papillomas was 3 times
Table 1
Anti-cancer effects of cinnamon and its analogues.
Ref Mechanism Dose/Route Cancer Type of cinnamon
[20] Inhibits transcriptionally MDR1 expression by suppression of AKT and STAT3pathway. NA Breast cancer, Lung
cancer, and colon
cancer
CB-PIC
[21] Inhibits tumor growth in vivo, stimulates sub-G1 accumulation in hypoxic situations by
inducing ERK and AMPKa, inhibits viability under hypoxia, suppresses the expression of
AKT,HIF-1a, and mTOR in hypoxia
NA Colon cancer CB-PIC
[22] Inhibits tumor growth, Stimulates cyclin B1 expression and G2/M cell cycle arrest 1.61e2.83 mg/mL Breast cancer, Colon
cancer
BCA (CB403)
[23,24] Suppresses tumor growth and formation by down-regulation of the ROS scavengers, such as
metallothionein1/2
NA Hepatocellular
carcinoma
BCA
[25] Stimulates cell death by up-regulatingEGR1, Suppresses cell viability by nuclear
translocalization of EGR1 via inducing importin-7
19.8e23.5 Prostate cancer BCA
[26] DJ-1 protects breast cancer cells against oxidative stress through inducing nuclear
translocation-independent Nrf2 signaling pathway
46.57 Breast cancer BCA
[27] Stimulates stronger anti-proliferative activities in RK3E-ras than in RK3E cells. >30
9.7
kidney cancer BCA
[28] Suppresses LPS and concanavalin A (Con A)-stimulated lymphocyte proliferation through
arresting the cell cycle at the G1 phase,
Stimulates T cell maturation.
NA Mouse splenocyte
cultures
BCA and HCA
[29] Indicates anti-tumorigenic effects via stimulating G2/M phase arrest <10 Breast cancer, Colon
cancer
BCA and HCA
[30] Suppresses growth of tumor cells in vivo and in vitro. 0.63e8.1 mg/mL Colon cancer BCA and HCA
[31] Stimulates G2/M phase cell cycle arrest by induction of PARP cleavage expression,
Suppresses tumor cell growth in vivo and in vitro.
16.8 Colon cancer Hydroxylamine
Derivatives
[32] Suppresses tumor metastasis in vivo, stimulates EMT via inhibition of snail by GSK-3b
nuclear translocalization and induction of E-cadherin, suppresses invasion via inhibition of
the Sp1/Id-1 signaling pathway by KLF17up-regulation.
NA Breast cancer HCA
[33] Suppresses cell invasion by pepsin clearance in a 2-macroglobulin-dependent manner via
inducing the cysteine thiol oxidation condition of the LRP1 extracellular domain
NA Breast cancer HCA
[34] Potently suppresses farnesyl protein transferase (FPTase) NA Colon cancer HCA
[35] Suppresses tumor growth in vivo 20.2e40.5 Oral squamous cell HCA
[36] Suppresses cell growth in vivo and in vitro. NA Various cancers HCA
[37] Suppresses protein isoprenylation, decreases proliferation of the tumor cells, decreases
invasion by down-regulating collagenase, MMP2, HLA-A3 and type IV
1e4.5mM Lung carcinoma,
Melanoma,
Glioblastoma and
Prostate cancer
Cinnamic acids
[38,39] Suppresses estrogen and androgen generation by inhibition of 17b-HSD type 1and17b-
hydroxysteroid dehydrogenase (AKR1C3)
NA Hormone-dependent
cancer
Cinnamic acids
[40] Inhibits tumor growth in vivo, suppresses tumor cell proliferation, stimulates G2/M cell
cycle arrest by suppressing Cdc25B phosphatase
0.6e10 Colon cancer, Breast
cancer
Dimeric
Cinnamaldehydes
[41] Synergizes cytotoxic impacts of cytokine-stimulated killer cells to K562 cells NA Leukemia Cinnamaldehyde
[42] Stimulates oxidative stress reaction, increases SRXN1, TXNRD1, HMOX1, andCDKN1A
expression, suppresses the TNF-a-stimulated expression of IL-8andthe NF-kB
transcriptional function, inhibits invasiveness, tumor growth, and proliferation of
melanoma cells
6.3 Melanoma Cinnamaldehyde
[43] Suppresses protein generation by trapping sulfhydryl-containing amino acid in cells NA Leukemia Cinnamaldehyde
[44] Inhibits cancer cell growth as well as suppresses the migration of tumor cells by MMP-2
down-regulation
0.36 Breast cancer Cinnamaldehyde
[45] Promotes efﬁcacy OXA and 5-FU efﬁcacy, causes a synergistic impact on apoptosis and
inhibits the drug-metabolizing genes, such as ERCC1, TS, BRCA1 and TOPO1
9.12e9.48 Colon cancer Cinnamaldehyde
[46] Increases the expression of cyclin B1 as well as tubulin accumulation 1.2e86.4 Colon cancer, Breast
cancer
Cinnamaldehyde,
BCA, HCA, and FHCA
[47] Increased PARP cleavage, increased PARP cleavage 9.76 Human hepatoma cells Cinnamaldehyde
[48] Compounds have reactive nucleophiles, including GSH and sulfhydryl groups, stimulates the
expression of Nrf2, and suppresses thioredoxinreductase (TrxR)
1.6e7 Colon cancer Cinnamaldehyde,
BCA, HCA, and FHCA
[49] Up-regulates Nrf2 protein, increases colon cancer cell protection and cellular glutathione
against oxidative stress, activates an Nrf2 antioxidant response
NA Colon cancer Cinnamaldehyde,
BCA, HCA, and FHCA
[50] Stimulates cell cycle arrest at the G2/M phase 1.7e19.77 Cisplatin-resistant
human ovarian cancer
Cinnamaldehyde
[51] Induces MAPK pathway-related gene, such asERKp38andJNK, stimulates cell cycle arrest at
the S phase
<0.5 Human hepatoma Cinnamaldehyde
[52] Stimulates G2/M cell cycle arrest through regulating two signaling proteins, inhibits cyclin B
protein expression and induction of p38
MAPK expression
NA Leukemia CE
[53] Down-regulates the expression of Her-2 oncoprotein, reduces cell migration by a decrease
in the expression of MMP-2
NA Cervical cancer CE
[54] Suppresses tumor growth and angiogenesis by inhibition of the VEGF2 signaling pathway NA Breast cancer CE
[55] Inhibits angiogenesis and tumor growth through down-regulating tumor-related growth
factors such as HIF-1, Cox-2, TGF-b, VEGF-aand EGF, induces killing function of CD8þTcells
by up-regulating cytolytic molecules (TNF-a and IFN-g)and granzymes B and C
NA Melanoma CE
CB-PIC: cinnamaldehyde derivative (E)-4-((2-(3-oxopop-1-enyl)phenoxy)methyl) pyridinium malonic acid; BCA: 20-Benzoyloxycinnamaldehyde; HCA: 20-hydrox-
ycinnamaldehyde; FBCA: 5-ﬂuoro-2-benzoyloxycinnamaldehyde; CE: Cinnamon extract.
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tumor-bearing subjects. Eugenol signiﬁcantly limited carcinogen-
esis at the dysplastic phase with a thickened epithelial layer or
acanthosis, while the traits in the control group showed developed
squamous cell carcinoma features including keratin pearl genera-
tion, acanthosis, and hyperkeratosis [18]. Signiﬁcant changes in the
cellular morphology were following combined treatment of pros-
tate cancer PC-3 cells with 2-methoxyestradiol (0.5 mM) and
eugenol (41 mg/ml) for 24 h, compared with each treatment alone
[17].
IL-1b is an inﬂammatory cytokine that contributes to carcino-
genesis. In HeLa cells, administration of eugenol suppressed IL-1b
expression compared with the control group [14]. It has been
indicated that pre-treatment with eugenol impedes tumorigenesis
in vivo via a signiﬁcant inhibition of 12-O-tetradecanoylphorbol-
13-acetate (TPA)-induced up-regulation in the expression of pro-
inﬂammatory mediators, including interleukin-6 (IL-6), prosta-
glandin E2 (PGE 2) and tumor necrosis factor-alpha (TNF-a). The
expression of these factors was nearly similar to control levels
when pre-treated with eugenol for 30min prior to exposure to TPA
[19]. The expression of COX-2 in HeLa cells was considerably
diminished by eugenol treatment [14]. iNOS and COX-2 transcrip-
tion levels in a TPA-induced skin cancer model were also limited by
eugenol pre-treatment [19]. It was also demonstrated that pre-
treating with eugenol hinders DMBA croton oil-mediated skin
carcinogenesis in mice via a reduction in the translation and tran-
scription levels of two oncogenes, c-Myc and H-ras. The expression
was decreased by 40% for c-Myc and by 28% for H-ras compared
with the controls.
Anti-tumor properties of cinnamon and its analogues in various
cancers are listed in Table 1.3. Apoptosis and cancer
Deregulation in programmed cell death or apoptosis contribute
signiﬁcantly to tumor pathogenesis by allowing neo-plastic cells to
stay alive, even in the presence of oxidative stress and hypoxia [56].
Cancer may be regarded as an outcome of a series of geneticFig. 3. Mechanisms that contribute to caalterations that cause the transformation of normal cells to malig-
nant cells [57]. Kerr et al. found an inverse association between
apoptosis and tumor progression, hyperplasia and formation of
abnormal cells [58]. Disturbed apoptosis contributes to carcino-
genesis. Researchers have found numerous mechanisms by which
an abnormal cell can suppress apoptosis and acquire apoptosis
resistance. In general, causative mechanisms of apoptosis evasion
are classiﬁed into three categories: i. impaired balance of pro-
apoptotic and anti-apoptotic proteins, ii. decreased caspase activ-
ity, and iii. dysfunction in death receptors signaling. Fig. 3 sum-
marizes the mechanisms contributing to apoptosis evasion and
carcinogenesis.
It has been indicated that several proteins have pro-apoptotic or
anti-apoptotic activities in cells. The ratio of pro- and anti-apoptotic
proteins is pivotal in the modulation of cell death. In addition, it has
been demonstrated that the modulation of apoptosis process
through up- or down-regulation of particular genes (ﬁnal modu-
latory proteins) plays an important role in carcinogenesis.
There are two general classes of caspases. One class, including
caspase-1, -4, -5, -13, and 14 contribute to cytokine processing
during inﬂammatory conditions. Another class including caspase-2,
-3. 6, 7,-8, 9 and 10 has a major role in apoptosis. Never-
theless, it has been found that “initiator caspases” comprising
caspase-2, -8, -9 and -10 initiate apoptosis, while caspase-3, -6 and
-7, known as effector caspases, mediate the cleavage of cellular
components during apoptosis [59]. Caspases play a signiﬁcant role
in initiating and executing apoptosis. Thus, dysfunction or dereg-
ulation of caspases can lead to impaired apoptosis and culminate in
carcinogenesis. Down-regulation of caspase-9 is a frequent obser-
vation in patients with colorectal cancer and is associatedwith poor
clinical outcomes [60]. Devarajan et al. reported that the levels of
caspases-3 mRNA in commercially accessible total RNA samples
from ovarian, cervical and breast tumors were either undetectable
(cervical and breast) or signiﬁcantly declined (ovarian). They also
reported that through reinstating the expression of caspase-3,
apoptosis sensitivity of caspase-3-deﬁcient breast cancer cells
(MCF-7) in response to anti-cancer drugs might be increased. This
indicates that survival of breast cancer cells might be caused byrcinogenesis and apoptosis evasion.
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more than one caspase may be down-regulated involves in the
progression and growth of tumour cells. Fong et al. found co-
downregulation of capase-8 and -10. They suggested that this can
play a role in the pathogenesis of choriocarcinoma [62].
Death receptors and their ligands play an essential role in the
external pathway of apoptosis. TNFR1 that is referred to as Fas and
DR1, is recognized by CD95 (also known as APO-1 or DR2). Other
receptors are DR6, DR5 (or TRAIL-2), DR4 [or TNF-associated
apoptosis, inducing ligand receptor 1 (TRAIL-1) or APO-2], DR3
(or APO-3), nerve growth factor receptor (NGFR), and ectodysplasin
A receptor (EDAR) [61]. Following the stimulation of these re-
ceptors by death signals, somemolecules bind to the death domain,
leading to the activation of the related signaling processes. Never-
theless, death receptor ligands can also bind to decoy death re-
ceptors, which do not have a death domain [63]. Numerous
abnormalities in death signaling pathways have been speciﬁed,
which may result in evading from external pathway of apoptosis.
Disorders are caused by down-regulation of death receptors,
impairment of their functions or decreased death signals leading to
decline in apoptosis. It has been indicated that down-regulation of
the expression of surface receptors is a mechanism of acquired drug
resistance. Also, down-regulation of CD95 expression contributes
to therapy-resistant leukemia or neuroblastoma cells [64,65].
Moreover, it has been found that a decrease in the membrane
expression of death receptors results in evading from the death
signaling pathways in several cancers [66]. Reesink-Peters et al.
conducted a study to examine whether modiﬁcations of theTable 2
Targeting apoptosis by Cinnamon and its analogues.
Ref Model Dose/Route Canc
[81] In vitro 10, 20, 40, 80, 160 and 320 mg/ml Cervi
[82] In vitro NA Colon
[83] In vitro 12.5 Colon
[84] In vitro 3.3e70.8 Breas
[7] In vitro, in vivo 0.5mg/ml,400 mg/g Oral Lymp
and c
[85] In vitro NA Hum
[86] In vitro 30.7 Leuk
[87] In vitro 2mmol Hum
[88] In vivo Cinnamon at a dose of 100ml, Oral, 8 weeks Colon
[89] In vitro 2, 1, 0.1 and 0.01mg/ml Leuk
[90] In vitro and in vivo 0 mM, 10 mM and 40 mM, injection of 200 mL Hepa
[91] In vitro 5, 10, 50, 100, 200 and 300 mM Prost
Canc
[92] In vitro 5, 10, 25, 50, 75, and 100 mM Leuk
[93] In vitro 10e100 mg/mL Breas
[94] In vitro 500 mM Cervi
[95] In vivo and in vitro 5 or 20mg/kg of Leuk
[96] In vitro and in vivo 0, 10, 20, 40, 80 and 160 mM, Injection of 5, 10,
or 20mg/kg/day of cuminaldehyde
Color
[97] In vitro 50 mM 00000 Prost
[98] In vitro and in vivo Different concentration, Injection of 10mg/kg Hepa
[99] In vitro 0.5, 1, 5 and 10mg/ml Breas
[100] In vitro and In vivo Different concentration, Injection of a 200 mL Hum
[101] In vivo and in vitro 10mg/ml, oral cinnamon 0.3mg/g. Ovar
[102] In vitro 1mg/mL Cervi
[103] In vitro various concentrations of cinnamon Breas
[104] In vivo and in vitro Different doses of cinnamon, 400 mg/g oral Mela
[105] In vitro NA Colon
[106] In vivo 500mg Oral
[107] In vitro 2, 4, 6, 8, and 10 mm Colon
[108] In vivo and in vitro 120mg/kg,
25 mM,
Mela
[109] In vivo and in vitro Different doses Color
[8] In vitro 0.0, 0.05, 0.075,
0.10, and 0.20mg/mL
Hem
BCA: 20-Benzoyloxycinnamaldehyde; HCA: 20-hydroxycinnamaldehyde; CE: Cinnamo
Cinnamaldehyde-Magnetite Nanoparticles; 2-MCA: 2-Methoxycinnamaldehyde; CPO: b-expression of death ligands and receptors within various phases of
cervical carcinogenesis are associated with interaction between
apoptosis and proliferation. They suggested that decrease in Fas
expression and dys-regulation of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL),DR4, DR5, and FasL could cause
cervical carcinogenesis in cervical intra-epithelial neoplasia (CIN)-
cervical cancer sequence [67]. It should be noted that any distur-
bance in apoptosis machinery might have a detrimental impact,
thus suggesting this process as a pivotal target for cancer treatment.
Drugs or strategies restoring apoptotic signaling pathways toward
normal patterns are potentially able to eliminate cancer cells.
4. Cinnamon targets apoptosis in cancer
Apoptosis or programmed cell death is a complex interaction
between several molecules and pathways. Generally, CE and its
active compounds can affect apoptosis progression inmany cancers
(Table 2, Fig. 4). It has been demonstrated that caspase-3 activity is
stimulated by CE in an in vivomelanomamodel and in B16F10 cells.
However, the level of procaspase-3 (inactive form) did not change,
and the expression of AP1 and NF-kB as well as transcription and
translation of their target genes such as BcL-xL, Bcl-2 and survivin
were signiﬁcantly decreased [68].
Eugenol is one of the most signiﬁcant active ingredient of cin-
namon, which induces apoptosis in promyelocytic leukemia cell
line HL-60 in a dose- and time-dependent manner via enhance-
ment of DNA fragmentation and reduction of mitochondrial po-
tential by generating ROS [16]. Also, eugenol increased ROSer Type of cinnamon
cal cancer CE
cancer HCA
cancer HCA
t cancer, Colon cancer, Lung cancer BCA
homa, melanoma, cervix cancer
olorectal cancer
Cinnamic aldehyde and cinnamylaldehyde
an hepatoma cells Cinnamaldehyde
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Caryophyllene oxide; PCB2: Procyanidin-B2.
Fig. 4. Cinnamon and apoptosis in cancer.
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HL-60 cells with 40 mM eugenol for 4 h led to signiﬁcant DNA
fragmentation through cleavage at inter-nucleosomal linker re-
gions, which form a clear DNA ladder.
Apoptosis induction by eugenol is mediated by DNA fragmen-
tation and proteolytic cleavage of caspase-3 and -9 from their
inactive forms. Although a considerable depletion of the amount of
bcl-2 protein and an increased cytochrome c release were observed
at this concentration of eugenol, procaspase-8 cleavage had no
signiﬁcant impact [16]. An in vivo investigation showed that
following pre-treatment with eugenol, the apoptotic index was
increased 1.5 fold in DMBA/TPA induced murine skin carcinogen-
esis through up-regulation of p53 p21WAF1 expression. Conse-
quently, this study conﬁrmed the effectiveness of eugenol in
apoptosis regulation [19]. Moreover, eugenol potentially regulates
the Bax:Bcl2 ratio and up-regulates caspase-3 activity in chemically
induced murine skin carcinogenesis [18].
Eugenol also caused a dose-dependent up-regulation in the
amount of caspase-3 activity in HeLa cells. Furthermore, eugenol
had chemosensitizing effects and its combination with a conven-
tional chemotherapeutic drug, gemcitabine (150 mM eugenol with
15mM and 25mM gemcitabine), synergistically ampliﬁed caspase-
3 activities compared with each agent alone [14]. In addition,
another study indicated the potential of eugenol in apoptosis in-
duction; its administration with 2-methoxy-estradiol signiﬁcantly
down-regulated Bcl-2 protein, up-regulated pro-apoptotic protein
Bax, and reduced mitochondrial membrane potential in prostate
cancer PC-3 cell [17].
It was found that cinnamaldehyde (40 mM), similar to eugenol,
induced apoptosis in HL-60 cells via inter-nucleosomal DNA frag-
mentation followed by chromatin condensation and degradation ofnuclei. Moreover, it signiﬁcantly up-regulated proteolytic cleavage
of procaspase-3 and procaspase-9, increased caspase-9 and
caspase-3 activation, declined mitochondrial transmembrane po-
tential, and increased cytochrome c release into the cytosol [69]. At
30 mM, cinnamaldehyde showed signiﬁcant anti-carcinogenic ef-
fects on liver cancer cell line HepG2 through reducing anti-
apoptotic protein Bcl-XL and inducing pro-apoptotic proteins Bax
and p53 in a time-dependent manner. After 24 h of treatment with
cinnamaldehyde, the expression of Bcl-XL was fully inhibited.
Moreover, cinnamaldehyde with the same dose up-regulated the
expression of CD95 (APO-1/CD95) and cleaved poly (ADP-ribose)
polymerase (PARP) [70]. It has been indicated that a low concen-
tration of cinnamaldehyde (1 mM) induces apoptosis by up-
regulating caspase-8, Bax and Bid activities, and reducing the
expression of anti-apoptotic proteins (Mcl-1 and Bcl-2) in the
hepatoma cell line PLC/PRF/5 in a time-dependent manner (6, 12,
and 24 h) [71]. One of the cinnamaldehyde isomers called trans-
cinnamaldehyde is able to enhance apoptosis in the myelogenous
leukemia cell line K562, which is mediated by decreasing the
mitochondrial trans-membrane potential. This isomers also con-
tributes to the increased expression of Fas/CD95 [41]. Fig. 4 depicts
the mechanisms through which cinnamaldehyde and its de-
rivatives function as anti-carcinogenic agents [72].
It has been conﬁrmed that cinnamaldehyde is an extremely
unstable compound in serum due to its aldehyde group. Thus,
modiﬁcation of aldehyde group with hydroxylamine and synthesis
of cinnamyl compounds without the aldehyde group were con-
ducted by Shin et al. [73]. PARP and caspase-3 cleavage in SW620
and HCT116 colon cancer cells were increased by hydroxylamine
derivatives at concentrations ranging from 20 to 40 mM [73].
Caspase-dependent apoptosis was induced by cinnamaldehyde
S. Sadeghi et al. / European Journal of Medicinal Chemistry 178 (2019) 131e140138(40 mM) in HL-60 leukemia cell line via induction of ROS generation,
cytochrome c accumulation in cytoplasm, activation of caspase-3
and caspase-9, and reduction of the mitochondrial trans-mem-
brane potential [69].
20-benzoyloxycinnamaldehyde (BCA) and 20-hydrox-
ycinnamaldehyde (HCA) are other cinnamon compounds which
exert their therapeutic effects on various diseases such as cancer via
affecting several biological mechanisms [6]. Gan et al. indicated
that apoptosis is induced by BCA (40 mM) through caspase-
dependent and caspase-independent pathways in HCT116 colon
cancer cells [74].
In colon cancer cells, apoptosis is induced by HCA through extra-
cellular signal regulated kinase (ERK)-dependent inactivation of
NF-kB, or suppressing the DNA-binding activities of AP-1 and
down-regulation of c-Fos and c-Jun expression [75,76]. Moreover,
there is an association between HCA-induced and BCA-induced
apoptosis with the inhibition of 26S proteasome activity in colon
cancer cells [77]. Nevertheless, Gan et al. indicated that 26S pro-
teasome suppression does not contribute to HCA-induced and BCA-
induced apoptosis of HEK293 cells [74]. Previous investigations
have demonstrated that BCA suppresses the proliferation of cells in
a more effective manner than HCA [78]. Hitherto, in vitro and
in vivo studies have shown that BCA is quickly hydrolyzed to HCA,
and is subsequently transformed to O-coumaric acid during a few
hours [79,80]. It was found that cell proliferation is more efﬁciently
inhibited by BCA compared with HCA. This might be caused by
variations in the cell permeability to compounds; the cell mem-
brane is more permeable to BCA due to the existence of higher
hydrophobic groups in this compound.
5. Conclusion
Due to the increasing prevalence of malignancies worldwide
and side effects of the current therapies, ﬁnding novel therapies is
an urgent medical need. Alternative or complementary treatments
from herbal sources have been noticed owing to their potential
safety and efﬁcacy in interfering with the oncogenic molecular
pathways. According to the extant data, cinnamon and its derivates
are natural compounds that possess antitumor properties. This
review highlighted the role of cinnamon in the regulation of
apoptosis as an essential signaling pathway involved in cancer
progression. However, further experimental studies should be
conducted to substantiate the anticancer activity of cinnamon,
particularly based on its apoptotic effects.
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